Spruce Biosciences, Inc. Comprehensive Income
Spruce Biosciences, Inc. (SPRB) reported Comprehensive Income of -$53.04 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-04-15.
Financial Statements › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2025-04-15
- Spruce Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-12-31 was -$23.56M.
- Spruce Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-09-30 was -$8.67M.
- Spruce Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-06-30 was -$9.18M.
- Spruce Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-03-31 was -$11.63M.
- Spruce Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$53.04M.
- Spruce Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$47.36M.
- Spruce Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$46.55M.
- Spruce Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2021 was -$42.48M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$23.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -$32.23M derived: sum of 2 quarters · filed 2025-04-15 | -$41.41M derived: sum of 3 quarters · filed 2025-04-15 | -$53.04M 10-K · filed 2025-04-15 |
| 2024-09-30 | -$8.67M 10-Q · filed 2024-11-12 | -$17.85M derived: sum of 2 quarters · filed 2024-11-12 | -$29.48M 10-Q · filed 2024-11-12 | -$39.42M derived: sum of 4 quarters · filed 2025-04-15 |
| 2024-06-30 | -$9.18M 10-Q · filed 2024-08-12 | -$20.81M 10-Q · filed 2024-08-12 | -$30.75M derived: sum of 3 quarters · filed 2025-04-15 | -$43.05M derived: sum of 4 quarters · filed 2025-04-15 |
| 2024-03-31 | -$11.63M 10-Q · filed 2024-05-13 | -$21.57M derived: sum of 2 quarters · filed 2025-04-15 | -$33.87M derived: sum of 3 quarters · filed 2025-04-15 | -$46.56M derived: sum of 4 quarters · filed 2025-04-15 |
| 2023-12-31 | -$9.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -$22.25M derived: sum of 2 quarters · filed 2025-04-15 | -$34.94M derived: sum of 3 quarters · filed 2025-04-15 | -$47.36M 10-K · filed 2025-04-15 |
| 2023-09-30 | -$12.30M 10-Q · filed 2024-11-12 | -$24.99M derived: sum of 2 quarters · filed 2024-11-12 | -$37.41M 10-Q · filed 2024-11-12 | -$48.24M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$12.69M 10-Q · filed 2024-08-12 | -$25.11M 10-Q · filed 2024-08-12 | -$35.94M derived: sum of 3 quarters · filed 2024-08-12 | -$47.37M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$12.42M 10-Q · filed 2024-05-13 | -$23.25M derived: sum of 2 quarters · filed 2024-05-13 | -$34.68M derived: sum of 3 quarters · filed 2024-05-13 | -$46.70M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$10.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$22.26M derived: sum of 2 quarters · filed 2024-03-18 | -$34.28M derived: sum of 3 quarters · filed 2024-03-18 | -$46.55M 10-K · filed 2024-03-18 |
| 2022-09-30 | -$11.43M 10-Q · filed 2023-11-13 | -$23.45M derived: sum of 2 quarters · filed 2023-11-13 | -$35.73M 10-Q · filed 2023-11-13 | -$45.08M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$12.02M 10-Q · filed 2023-08-14 | -$24.30M 10-Q · filed 2023-08-14 | -$33.65M derived: sum of 3 quarters · filed 2023-08-14 | -$45.08M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$12.27M 10-Q · filed 2023-05-15 | -$21.62M derived: sum of 2 quarters · filed 2023-05-15 | -$33.06M derived: sum of 3 quarters · filed 2023-05-15 | -$44.86M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$9.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$20.79M derived: sum of 2 quarters · filed 2023-03-16 | -$32.59M derived: sum of 3 quarters · filed 2023-03-16 | -$42.48M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$11.43M 10-Q · filed 2022-11-10 | -$23.24M derived: sum of 2 quarters · filed 2022-11-10 | -$33.12M 10-Q · filed 2022-11-10 | -$41.46M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$11.80M 10-Q · filed 2022-08-10 | -$21.69M 10-Q · filed 2022-08-10 | -$30.03M derived: sum of 3 quarters · filed 2022-08-10 | -$39.62M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$9.89M 10-Q · filed 2022-05-11 | -$18.23M derived: sum of 2 quarters · filed 2022-05-11 | -$27.81M derived: sum of 3 quarters · filed 2022-05-11 | -$34.26M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | -$8.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | -$17.93M derived: sum of 2 quarters · filed 2022-03-14 | -$24.37M derived: sum of 3 quarters · filed 2022-03-14 | -$29.54M 10-K · filed 2022-03-14 |
| 2020-09-30 | -$9.59M 10-Q · filed 2021-11-15 | -$16.03M derived: sum of 2 quarters · filed 2021-11-15 | -$21.20M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$6.45M 10-Q · filed 2021-08-10 | -$11.61M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |